Stauder R. The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients. Ann Hematol. 2012;91(9):1333–43.Stauder R. The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes...
41 The gain in life expectancy was 4 years when HSCT was performed in MDS patients with intermediate risk according to WPSS, in contrast to patients considered intermediate-1 risk according to IPSS.64 The difference between the 2 risk classifications is mainly based on the consideration of ...
In the last few years, the introduction of RIC regimens has resulted in a significant reduction of transplant-related toxicity and mortality, leading to a rapidly growing number of transplantations in elderly patients with hematologic diseases.30,38 Interestingly, IPSS-R maintained its prognostic effec...
Experience gained in hereditary iron-loading anemias indicates that the long-term consequences of iron toxicity are preventable and reversible by effective iron chelation therapy (ICT). With the introduction of orally effective iron chelators that are easy to take and suitable for use in elderly ...
Furthermore, only young and fit patients can be candidates for HSCT, due to higher mortality in the elderly and in patients with major comorbidities. The optimal timing of HSCT should take into account life expectancy without HSCT and quality of life. Some low-risk patients with persistent ...
Whether or not this has a positive effect on health-related quality of life should be the main question. 2. HRQoL Should Be the Primary Treatment Goal and Needs a Standardized Unit of Measurement Lower-risk myelodysplastic syndromes are known to occur predominantly in the elderly population, who...
Furthermore, only young and fit patients can be candidates for HSCT, due to higher mortality in the elderly and in patients with major comorbidities. The optimal timing of HSCT should take into account life expectancy without HSCT and quality of life. Some low-risk patients with persistent ...